Alteplase as a catheter locking solution: In vitro evaluation of biochemical stability and antimicrobial properties

被引:4
作者
Weck, S
Cheung, S
Hiraoka-Sutow, M
Patapoff, T
Semba, CP
机构
[1] Genentech Inc, Dept Pharmaceut Res & Dev, San Francisco, CA 94080 USA
[2] Genentech Inc, Dept Microbiol, San Francisco, CA USA
[3] Genentech Inc, Dept Vasc Med & Neurol, San Francisco, CA USA
[4] Stanford Univ, Div Cardiovasc & Intervent Radiol, Stanford, CA 94305 USA
关键词
TISSUE-PLASMINOGEN ACTIVATOR; ANTIBIOTIC-LOCK; STAPHYLOCOCCUS-AUREUS; INTERDIALYTIC PERIOD; HEPARIN; HEMODIALYSIS; PATENCY; COLONIZATION; INFECTION; EFFICACY;
D O I
10.1097/01.RVI.0000148154.30967.27
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: To reduce potential complications of fibrin deposition to catheter surfaces, there is increasing empiric use of alteplase as a catheter lock solution. The purpose is to evaluate the properties of alteplase when reconstituted in sterile water (SW) or bacteriostatic water (BW) for prolonged periods. MATERIALS AND METHODS: Alteplase in glass vials was reconstituted (1 mg/mL) with SW or BW (0.9% benzyl alcohol) in duplicates and stored at 37 degrees C. Biochemical assays were performed at days 0 and 7 and included optical clarity, protein concentration, percent protein monomer, and in vitro clot lysis activity. Microbiologic assays were performed on days 7 through 28 with use of a standardized antimicrobial effectiveness test (pass/fail) and pour-plate methods incubated at 22.5 degrees C (fungus, 3-7 days) or 32.5 degrees C (bacteria, 3-5 days). Organisms tested included Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans, and Aspergillus niger. RESULTS: Biochemical assay results were as follows: on day 0, all samples were clear/colorless; protein concentrations were 1.10 mg/mL +/- 0 in SW and 1.11 mg/mL +/- 0 in BW; percent protein monomer was 8.2% +/- 0.07 in SW and 98.6% +/- 0.07 in BW; and in vitro clot lysis activity (in percent of relative activity) was 100% in all samples. On day 7, all samples were clear/colorless, protein concentrations were 1.11 mg/mL +/- 0.07 in SW and 1.11 mg/mL +/- 0.07 in BW; percent protein monomer was 97.4% +/- 0.21 in SW and 96.1% +/- 0.21 in BW; and in vitro clot lysis activity (relative activity compared with day 0) was 91% +/- 2.8 in SW and 90% +/- 2.8 in BW. Microbiologic assays (US Pharmacopeia [USP] antimicrobial effectiveness test) yielded a failing result for alteplase reconstituted in SW and a passing result for alteplase reconstituted in BW. CONCLUSIONS: Alteplase reconstituted with SW or BW remains relatively stable with retained bioactivity when stored at 37 degrees C for as long as 7 days. Despite the biochemical similarities of the two solutions, only alteplase in BW met USP criteria as an effective antimicrobial solution. Further clinical evaluation is warranted.
引用
收藏
页码:379 / 383
页数:5
相关论文
共 25 条
[1]   Elimination of intraluminal colonization by antibiotic lock in silicone vascular catheters [J].
Andris, DA ;
Krzywda, EA ;
Edmiston, CE ;
Krepel, CJ ;
Gohr, CM .
NUTRITION, 1998, 14 (05) :427-432
[2]   Bacterial adhesion on polyurethane surfaces conditioned with thrombus components [J].
Baumgartner, JN ;
Cooper, SL .
ASAIO JOURNAL, 1996, 42 (05) :M476-M479
[3]   Filling hemodialysis catheters in the interdialytic period: Heparin versus citrate versus polygeline: A prospective randomized study [J].
Buturovic, J ;
Ponikvar, R ;
Kandus, A ;
Boh, M ;
Klinkmann, J ;
Ivanovich, P .
ARTIFICIAL ORGANS, 1998, 22 (11) :945-947
[4]   Lack of antimicrobial activity of sodium heparin for treating experimental catheter-related infection due to Staphylococcus aureus using the antibiotic-lock technique [J].
Capdevila, JA ;
Gavaldà, J ;
Fortea, J ;
López, P ;
Martin, MT ;
Gomis, X ;
Pahissa, A .
CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (04) :206-212
[5]  
*CGMP, 2004, DIV MAN PROD QUAL HF
[6]   Efficacy of tissue plasminogen activator administration on patency of hemodialysis access catheters [J].
Daeihagh, P ;
Jordan, J ;
Chen, J ;
Rocco, M .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2000, 36 (01) :75-79
[7]  
*FDA, 2000, FDA ISS WARN TRIC DI
[8]   Indications and complications of intravenous devices for chemotherapy [J].
Freytes, CO .
CURRENT OPINION IN ONCOLOGY, 2000, 12 (04) :303-307
[9]  
*GEN INC, CATHFL ACT FULL PRES
[10]   THE GASPING SYNDROME AND BENZYL ALCOHOL POISONING [J].
GERSHANIK, J ;
BOECLER, B ;
ENSLEY, H ;
MCCLOSKEY, S ;
GEORGE, W .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (22) :1384-1388